PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-31.01%
Both yoy net incomes decline, with VET at -66.37%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-23.63%
Both reduce yoy D&A, with VET at -43.19%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-26.56%
Negative yoy deferred tax while VET stands at 98.68%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
253.33%
SBC growth while VET is negative at -78.75%. John Neff would see competitor possibly controlling share issuance more tightly.
-35.14%
Both reduce yoy usage, with VET at -144.62%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-34.13%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
19.05%
Inventory growth of 19.05% while VET is zero at 0.00%. Bruce Berkowitz would see a moderate build that must match future sales to avoid risk.
44.37%
AP growth of 44.37% while VET is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-35.14%
Both reduce yoy usage, with VET at -144.62%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
124.07%
Well above VET's 102.54%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-22.19%
Both yoy CFO lines are negative, with VET at -55.32%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-4.92%
Both yoy lines negative, with VET at -7.77%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
-1249.20%
Both yoy lines negative, with VET at -104.58%. Martin Whitman sees an overall caution or integration phase for both companies’ expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
334.85%
Less 'other investing' outflow yoy vs. VET's 1716.26%. David Dodd would see a stronger short-term cash position unless competitor invests more wisely.
-248.55%
Both yoy lines negative, with VET at -51.25%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
98.59%
Debt repayment similar to VET's 96.91%. Walter Schloss sees parallel liability management or similar free cash flow availability.
No Data
No Data available this quarter, please select a different quarter.
62.76%
Repurchase growth above 1.5x VET's 19.33%. David Dodd would see a strong per-share advantage if the share price is reasonably valued.